Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Blincyto (Resubmission) Blinatumomab Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete
Blincyto Blinatumomab Acute Lymphoblastic Leukemia (pediatric) Reimburse with clinical criteria and/or conditions Complete
Rydapt Midostaurin Acute Myeloid Leukemia Reimburse Complete
Vyxeos daunorubicin and cytarabine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Venclexta venetoclax Acute myeloid leukemia Do not reimburse Complete
Venclexta venetoclax Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Onureg azacitidine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Mylotarg Gemtuzumab Ozogamicin Acute Myeloid Leukemia (AML) Reimburse Complete
TBC ivosidenib Acute myeloid leukemia (AML) Received
Daurismo Glasdegib Acute Myeloid Leukemia (AML) Do not reimburse Complete